Mittwoch, 25. Dezember 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Rekrutierend

NCT-Nummer:
NCT06140836

Studienbeginn:
Dezember 2023

Letztes Update:
07.08.2024

Wirkstoff:
Repotrectinib, Crizotinib

Indikation (Clinical Trials):
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Bristol-Myers Squibb

Collaborator:
Zai Lab (Shanghai) Co., Ltd.

Studienleiter

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

Kontakt

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Kontakt:
Phone: 855-907-3286
E-Mail: Clinical.Trials@bms.com
» Kontaktdaten anzeigen
First line of the email MUST contain the NCT# and Site #.

Studienlocations
(3 von 142)

Interdisziplinäres Brustzentrum am Klinikum Esslingen
Hirschlandstraße 97
73730 Esslingen am Neckar
(Baden-Württemberg)
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Martin Faehling, Site 0124
Phone: +4971131032402
» Ansprechpartner anzeigen
Local Institution - 0136
30912 Augusta
United StatesZurückgezogen» Google-Maps
Local Institution - 0061
53226 Milwaukee
United StatesZurückgezogen» Google-Maps
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)
1431 Buenos Aires
ArgentinaRekrutierend» Google-Maps
Ansprechpartner:
Vanina Wainsztein, Site 0106
Phone: 5491149809013
» Ansprechpartner anzeigen
Fundação Faculdade Regional de Medicina de São José do Rio Preto
15090000 São José do Rio Preto
BrazilRekrutierend» Google-Maps
Ansprechpartner:
BRUNO CEZAR UCHÔA JÚNIOR, Site 0037
Phone: 11997722237
» Ansprechpartner anzeigen
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec
G8Z 3R9 Trois-Rivières
CanadaRekrutierend» Google-Maps
Ansprechpartner:
Jean Sebastien Aucoin, Site 0123
Phone: 8196973333
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Brief Summary:

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and

crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive

non-small cell lung cancer (NSCLC).

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Participant has histologically or cytologically confirmed diagnosis of locally

advanced or metastatic NSCLC

- Participant has a ROS1 gene rearrangement/fusion as detected by a local test.

- At least 1 measurable lesion according to RECIST v1.1, as assessed by the

investigator.

- Participants must not be exposed previously with TKIs that demonstrated activities

in ROS1-positive NSCLC

- Up to 1 prior line of systemic treatment for NSCLC is permitted

- ECOG Performance Status ≤ 2

Exclusion Criteria:

- Symptomatic brain metastases or symptomatic leptomeningeal involvement.

- History of previous cancer requiring therapy within the previous 2 years, except for

NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ

carcinoma that has been completely resected.

- Known tumor targetable co-mutations or rearrangements

- Clinically significant cardiovascular disease (either active or within 6 months

prior to enrollment)

Note: Other protocol-defined inclusion/exclusion criteria apply

Studien-Rationale

Primary outcome:

1. Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Time Frame - Up to 64 months)



Secondary outcome:

1. Overall Survival (OS) (Time Frame - Up to 87 months)

2. Overall Response Rate (ORR) as per BICR according to RECIST v1.1 (Time Frame - Up to 64 months)

3. ORR as per Investigator according to RECIST v1.1 (Time Frame - Up to 64 months)

4. Duration of Response (DOR) as per BICR according to RECIST v1.1 (Time Frame - Up to 64 months)

5. DOR as per Investigator according to RECIST v1.1 (Time Frame - Up to 64 months)

6. Time to Response (TTR) as per BICR according to RECIST v1.1 (Time Frame - Up to 64 months)

7. TTR as per Investigator according to RECIST v1.1 (Time Frame - Up to 64 months)

8. PFS as per Investigator according to RECIST v1.1 (Time Frame - Up to 64 months)

9. Time to intracranial progressions as per BICR according to RECIST v1.1 (Time Frame - Up to 64 months)

10. Number of participants with Adverse Events (AEs), Serious AEs (SAEs), AEs leading to study intervention discontinuation, and drug-related AEs (Time Frame - Up to 30 days after last dose)

11. Number of deaths (Time Frame - Up to 30 days after last dose)

12. Number of participants without at least a 3-point change in the Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) total score (Time Frame - Up to 30 days after last dose)

Studien-Arme

  • Experimental: Arm A
  • Active Comparator: Arm B

Geprüfte Regime

  • Repotrectinib (BMS-986472):
    Specified dose on specified days
  • Crizotinib (Xalkori):
    Specified dose on specified days

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.